ADAR1 Capital Management LLC Has $5.39 Million Stock Position in Xencor, Inc. (NASDAQ:XNCR)

ADAR1 Capital Management LLC decreased its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 31.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 234,607 shares of the biopharmaceutical company's stock after selling 107,655 shares during the quarter. Xencor comprises approximately 1.1% of ADAR1 Capital Management LLC's investment portfolio, making the stock its 21st biggest holding. ADAR1 Capital Management LLC owned about 0.34% of Xencor worth $5,391,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of XNCR. GAMMA Investing LLC boosted its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV lifted its holdings in Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 813 shares in the last quarter. Quarry LP grew its stake in Xencor by 111.4% in the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock valued at $80,000 after acquiring an additional 2,108 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock worth $93,000 after acquiring an additional 1,337 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new stake in shares of Xencor during the third quarter worth about $205,000.

Xencor Stock Up 7.8 %

XNCR traded up $0.62 during trading hours on Friday, hitting $8.54. 1,270,183 shares of the company's stock were exchanged, compared to its average volume of 616,139. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24. The stock's 50-day moving average is $13.07 and its two-hundred day moving average is $19.09. The stock has a market cap of $601.75 million, a price-to-earnings ratio of -2.67 and a beta of 0.90.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $52.79 million during the quarter, compared to analysts' expectations of $17.14 million. Sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on XNCR. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wells Fargo & Company lowered their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $34.38.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.